Overview

131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This trial is studying how well iodine I 131 metaiodobenzylguanidine together with combination chemotherapy works in treating patients who are undergoing an autologous peripheral stem cell for high risk or relapsed neuroblastoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Tehran University of Medical Sciences

Treatments:

3-Iodobenzylguanidine
Carboplatin
Etoposide
Etoposide phosphate
Melphalan